Skip to main content
. Author manuscript; available in PMC: 2020 May 12.
Published in final edited form as: Cancer Lett. 2018 Nov 10;442:483–490. doi: 10.1016/j.canlet.2018.11.008

Figure 3. Beclin 1 regulates Enzalutamide sensitivity.

Figure 3.

A. Comparing Beclin 1 expression between EnzS1-C4-2 & EnzS2-C4-2B and EnzR1-C4-2 & EnzR2-C4-2B cells (P, parental; R, resistant). B. Knock down and overexpression of BECN1 efficiencies in EnzS2-C4-2B and EnzR2-C4-2B cells, respectively. C-D. MTT assay demonstrated knocking down BECN1 expression (with 2 Sh-BECN1s) decreased Enz sensitivity in EnzS1-C4-2 (C) and EnzS2-C4-2B (D) cells. E. MTT assay demonstrated that combining Enz with ERK inhibitor treatment could partially reverse ShBECN1 decreased Enz-sensitivity in EnzS1-C4-2 cells. F-G. MTT assay demonstrated ectopic BECN1 expression in EnzR1-C4-2 (F) and EnzR2-C4-2B (G) cells re-sensitized Enzalutamide resistance.